What is the maximum dose and duration of colchicine (Colchicine) for a patient with pericarditis, considering factors such as impaired renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 16, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Maximum Colchicine Dosing for Pericarditis

For acute pericarditis, the maximum dose is 0.5 mg twice daily (1.0 mg total daily) for patients ≥70 kg or 0.5 mg once daily for patients <70 kg, continued for 3 months. 1, 2

Standard Dosing by Weight and Duration

Acute Pericarditis (First Episode)

  • Patients ≥70 kg: 0.5 mg twice daily (maximum 1.0 mg/day) 1, 2
  • Patients <70 kg: 0.5 mg once daily (maximum 0.5 mg/day) 1, 2
  • Duration: 3 months 1, 3, 2

Recurrent/Chronic Pericarditis

  • Same weight-based dosing as acute pericarditis 3
  • Duration: Minimum 6 months for recurrent disease 3
  • The European Society of Cardiology demonstrated that this regimen reduces recurrence rates from 55% to 24% at 18 months 3

Critical Dose Adjustments for Renal Impairment

Colchicine is contraindicated in severe renal impairment and requires substantial dose reduction in moderate-to-severe kidney disease. 1

Renal Dosing Algorithm

  • CrCl 30-50 mL/min (moderate impairment): Standard dose acceptable but requires close monitoring for toxicity 1
  • CrCl <30 mL/min (severe impairment): 0.3 mg once daily maximum 1
  • Dialysis patients: 0.3 mg twice weekly maximum 1, 4

FDA Maximum Dosing Limits

The FDA label specifies absolute maximum daily doses that should never be exceeded 4:

  • Without drug interactions: Maximum 1.2-2.4 mg/day 4
  • With P-gp inhibitors (cyclosporine, ranolazine): Maximum 0.6 mg/day 4
  • With protease inhibitors: Maximum 0.6 mg/day 4

Important Drug Interaction Adjustments

When colchicine is combined with strong CYP3A4 or P-gp inhibitors, the dose must be reduced to prevent fatal toxicity 4:

  • Patients on cyclosporine, clarithromycin, or protease inhibitors should receive maximum 0.3 mg once daily for prophylaxis 4
  • Patients with renal or hepatic impairment should not receive colchicine with these inhibitors 4

Treatment Algorithm

  1. Confirm diagnosis: Establish pericarditis using ≥2 clinical criteria before starting colchicine 1
  2. Assess renal function: Calculate CrCl to determine appropriate dosing 1, 4
  3. Review medications: Check for CYP3A4/P-gp inhibitors requiring dose adjustment 4
  4. Weight-based dosing: Use 0.5 mg once daily (<70 kg) or twice daily (≥70 kg) 1, 2
  5. Always combine with NSAIDs: Never use colchicine as monotherapy 3, 2
  6. Monitor with CRP: Continue until symptoms resolve and CRP normalizes 1, 2

Common Pitfalls to Avoid

  • Never exceed 1.0 mg/day in standard pericarditis treatment without specific indication 1, 2
  • Never use standard doses in severe renal impairment (CrCl <30) - this can cause fatal toxicity 1, 4
  • Never combine standard doses with strong CYP3A4 inhibitors (macrolides, statins increase toxicity risk) 5
  • Never stop before 3 months for acute pericarditis - inadequate duration increases recurrence risk from 16.7% to 37.5% 1, 6
  • Never use colchicine alone - it must be combined with aspirin or NSAIDs 3, 2

Safety Profile

Gastrointestinal intolerance is the most common side effect, occurring in 5-10% of patients 7, 8. This can be managed by:

  • Temporary dose reduction 7
  • Brief discontinuation 7
  • Diet modification 5

The CORP-2 trial demonstrated that colchicine at these doses has similar adverse event rates to placebo (7% vs 7%) with no serious adverse events reported 9, 8.

References

Guideline

Initial Treatment for Pericarditis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Pericarditis Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Colchicine Dosing for Chronic Pericarditis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Colchicine as an anti-inflammatory and cardioprotective agent.

Expert opinion on drug metabolism & toxicology, 2015

Research

Colchicine for pericarditis.

Trends in cardiovascular medicine, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.